Home  |  Contact

Cellosaurus LNCaP (CVCL_0395)

Cell line name LNCaP
Synonyms LNCAP; LNCap; Lymph Node Carcinoma of the prostate
Accession CVCL_0395
Resource Identification Initiative To cite this cell line use: LNCaP (RRID:CVCL_0395)
Comments Part of: ENCODE project common cell types; tier 3.
Doubling time: ~60 hours (DSMZ).
Microsatellite instability: Instable (MSI) (PubMed=23671654).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: Glycoproteome analysis by proteomics.
Omics: GPI-anchored proteins analysis by proteomics.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using proteomics.
Sequence variations Homozygous for AR p.Thr878Ala (c.2632A>G) (PubMed=22213130).
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_U984 (AILNCaP)CVCL_M126 (LNCaP 104-S)CVCL_M129 (LNCaP C-33)
CVCL_4783 (LNCaP C4)CVCL_M132 (LNCaP C5)CVCL_1379 (LNCaP clone FGC)
CVCL_M133 (LNCaP M)CVCL_4793 (LNCaP-abl)CVCL_3872 (LNCaP-CL1)
CVCL_8986 (LNCaP-CR)CVCL_V260 (LNCaP-CS10)CVCL_RA57 (LNCaP-EnzR)
CVCL_L160 (LNCaP-LN1)CVCL_5J24 (LNCaP-luc2)CVCL_9U27 (LNCaP-OM)
CVCL_L164 (LNCaP-Pro1)CVCL_5J03 (LNCaP-Red-FLuc)CVCL_4792 (LNCaP-Rf)
CVCL_D575 (LNGK9)CVCL_UD76 (LREX')CVCL_RW50 (MR42D)
CVCL_RW51 (MR42F)CVCL_RW52 (MR49C)CVCL_RW53 (MR49F)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): CLS; DSMZ; PubMed=11416159; PubMed=14518029; PubMed=25877200

Markers:
AmelogeninX (CLS)
X,Y (DSMZ; PubMed=11416159; PubMed=14518029; PubMed=25877200)
CSF1PO10,11
D13S31710,12 (CLS; PubMed=25877200)
10,11,12,13 (PubMed=14518029)
D16S53911
D18S5111,12
D21S1129,31.2 (CLS)
29,31.2,32.2 (PubMed=11416159)
29,32.2 (PubMed=14518029)
28,29,31.2 (PubMed=25877200)
D3S135816
D5S81811,12,13 (PubMed=25877200)
11,12 (CLS; DSMZ; PubMed=14518029)
D7S8209.1,10.3 (CLS; DSMZ)
9,11 (PubMed=14518029)
8.1,9.1,10.3 (PubMed=25877200)
D8S117912,14 (CLS; PubMed=14518029; PubMed=25877200)
12,13,14 (PubMed=11416159)
FGA19,20 (CLS; PubMed=14518029; PubMed=25877200)
19,20,21 (PubMed=11416159)
Penta D12,12.4
Penta E12,16 (CLS)
16 (PubMed=25877200)
TH019
TPOX8,9
vWA16,18
Web pages http://lncap.com/
https://en.wikipedia.org/wiki/LNCaP
http://141.61.102.20/mxdb/project/show/9191407937500
http://genome.ucsc.edu/ENCODE/protocols/cell/human/LNCaP_Crawford_protocol.pdf
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/l/cell-lines-detail-136.html
Publications

CLPUB00410
Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman A., Friedman M., Papsidero L.D., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A.
The LNCaP cell line -- a new model for studies on human prostatic carcinoma.
(In) Models for prostate cancer; Murphy G.P. (eds.); pp.115-132; Alan R. Liss; New York (1980)

PubMed=6831420
Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P.
LNCaP model of human prostatic carcinoma.
Cancer Res. 43:1809-1818(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=8687134
Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.
The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.
Anticancer Res. 16:815-820(1996)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H
Webber M.M., Bello D., Quader S.T.A.
Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.
Prostate 30:58-64(1997)

PubMed=10702678; DOI=10.1159/000015432
Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N., Isola J., Visakorpi T., Bergerheim U.S.R., Larsson C.
Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.
Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E
Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.
IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.
Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21
Russell P.J., Kingsley E.A.
Human prostate cancer cell lines.
Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)

PubMed=15486987; DOI=10.1002/pros.20158
Zhao H., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.
Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
Prostate 63:187-197(2005)

PubMed=22213130; DOI=10.1002/pros.22480
Spans L., Atak Z.K., Van Nieuwerburgh F., Deforce D., Lerut E., Aerts S., Claessens F.
Variations in the exome of the LNCaP prostate cancer cell line.
Prostate 72:1317-1327(2012)

PubMed=22278370; DOI=10.1074/mcp.M111.014050
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=24587179; DOI=10.1371/journal.pone.0090002
Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S., Joniau S., Lerut E., Claessens F.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
PLoS ONE 9:E90002-E90002(2014)

PubMed=24618588; DOI=10.1371/journal.pone.0091433
Chernobrovkin A.L., Zubarev R.A.
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
PLoS ONE 9:E91433-E91433(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26256267; DOI=10.1074/mcp.M115.047928
Shah P., Wang X., Yang W., Toghi Eshghi S., Sun S., Hoti N., Chen L., Yang S., Pasay J., Rubin A., Zhang H.
Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.
Mol. Cell. Proteomics 14:2753-2763(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.
J. Proteomics 139:77-83(2016)

PubMed=27036029; DOI=10.18632/oncotarget.8456
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001
Masuishi Y., Kimura Y., Arakawa N., Hirano H.
Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.
Data Brief 7:1302-1305(2016)

PubMed=29233929; DOI=10.1158/0008-5472.CAN-17-1924
Horning A.M., Wang Y., Lin C.-K., Louie A.D., Jadhav R.R., Hung C.-N., Wang C.-M., Lin C.-L., Kirma N.B., Liss M.A., Kumar A.P., Sun L., Liu Z., Chao W.-T., Wang Q., Jin V.X., Chen C.-L., Huang T.H.-M.
Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response.
Cancer Res. 78:853-864(2018)

PubMed=29660373; DOI=10.1016/j.bbagen.2018.04.012
Touat-Hamici Z., Bulteau A.-L., Bianga J., Jean-Jacques H., Szpunar J., Lobinski R., Chavatte L.
Selenium-regulated hierarchy of human selenoproteome in cancerous and immortalized cells lines.
Biochim. Biophys. Acta 1862:2493-2505(2018)

Cross-references
Cell line collections CLS; 300265/p761_LNCaP
DSMZ; ACC-256
Cell line databases/resources CLDB; cl3243
CCRID; 3111C0001CCC000040
LINCS_LDP; LCL-1298
Lonza; 109
TOKU-E; 3599
Ontologies BTO; BTO:0001321
CLO; CLO_0007365
EFO; EFO_0002071
MCCL; MCC:0000290
Biological sample resources BioSample; SAMN03472386
Chemistry resources ChEMBL-Cells; CHEMBL3307965
ChEMBL-Targets; CHEMBL612518
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSE99795
GEO; GSM91927
GEO; GSM482669
GEO; GSM525800
GEO; GSM784790
GEO; GSM816637
GEO; GSM816634
GEO; GSM844579
GEO; GSM945240
GEO; GSM945282
GEO; GSM1029460
GEO; GSM1029461
GEO; GSM1029462
GEO; GSM1029463
GEO; GSM1029464
GEO; GSM1029465
GEO; GSM1029466
GEO; GSM1029467
GEO; GSM1374622
GEO; GSM1374626
GEO; GSM2069518
GEO; GSM2069519
GEO; GSM2069520
GEO; GSM2069521
GEO; GSM2069522
GEO; GSM2069523
GEO; GSM2069524
GEO; GSM2069525
Other Wikidata; Q6459234
Polymorphism and mutation databases Cosmic; 704848
Cosmic; 721368
Cosmic; 721555
Cosmic; 755298
Cosmic; 759895
Cosmic; 801348
Cosmic; 850413
Cosmic; 850745
Cosmic; 850821
Cosmic; 869155
Cosmic; 918500
Cosmic; 920967
Cosmic; 921047
Cosmic; 922553
Cosmic; 923955
Cosmic; 943176
Cosmic; 948076
Cosmic; 949248
Cosmic; 1028648
Cosmic; 1028701
Cosmic; 1066237
Cosmic; 1070886
Cosmic; 1071481
Cosmic; 1071906
Cosmic; 1075275
Cosmic; 1172626
Cosmic; 1176618
Cosmic; 1330909
Cosmic; 1556120
Cosmic; 1689708
Cosmic; 1995486
Cosmic; 2537792
Cosmic; 2580128
Cosmic; 2585151
Cosmic; 2585228
Cosmic; 2651770
Cosmic; 2669169
Proteomic databases PRIDE; PXD000953
PRIDE; PXD000985
PRIDE; PXD002107
PRIDE; PXD002395
PRIDE; PXD003105
PRIDE; PXD003262